Leerink Partners analyst Danielle Antalffy maintained a Buy rating on Baxter International (NYSE:BAX) on Friday, setting a price target of $105, which is approximately 32.98% above the present share price of $78.96.
Antalffy expects Baxter International to post earnings per share (EPS) of $0.59 for the fourth quarter of 2021.
The current consensus among 9 TipRanks analysts is for a Moderate Buy rating of shares in Baxter International, with an average price target of $92.33.
The analysts price targets range from a high of $105 to a low of $80.
In its latest earnings report, released on 06/30/2021, the company reported a quarterly revenue of $3.1 billion and a net profit of $421 million. The company's market cap is $39.53 billion.
According to TipRanks.com, Leerink Partners analyst Danielle Antalffy is currently ranked with 5 stars on a 0-5 stars ranking scale, with an average return of 19.4% and a 63.75% success rate.
Founded in 1931 and based in Illinois, Baxter International, Inc. provides a portfolio of healthcare products. The company focuses on transformative innovation to deliver smarter, more personalized care for patients and providers. It operates through six global businesses: Renal Care, Medication Delivery, Pharmaceuticals, Clinical Nutrition, Advanced Surgery and Acute Therapies.